Drug Profile

IDE 161

Alternative Names: IDE-161

Latest Information Update: 23 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IDEAYA Biosciences
Class Antineoplastics; Small molecules
Mechanism of Action Poly ADP ribose glycohydrolase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

17 Feb 2026 IDEAYA plans a phase-I trial in Solid tumours (Combination therapy) in second quarter of 2026
30 Jan 2026 IDEAYA Bioscience has worldwide patent protection of IDE 161
25 Apr 2025 Pharmacodynamics data from the preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com